Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2025

Accounting Policies [Abstract]

Schedule of Reconciliation of the Company's net loss

The following table presents the significant segment expenses regularly provided to the CODM and a reconciliation to net loss (in thousands):


		Year Ended December 31,
		2025				2024

General and administrative expenses		$	13,660			$	13,659

Research and development expenses
Clinical trial			4,727				42,369
Formulation and CMC			3,805				2,270
Preclinical			129				1,845
Total direct research and development expenses			8,661				46,484
Personnel-related			5,367				3,689
Consulting and other			2,716				998
Total indirect and unallocated research and development expenses			8,083				4,687
Total research and development expenses			16,744				51,171
Total operating loss			(30,404	)			(64,830	)
Non-operating income			5,200				1,729
Income tax provision			1				1
Net Loss		$	(25,205	)		$	(63,102	)

Schedule of Depreciation of Property and Equipment Estimated Useful Lives

Property and equipment are recorded at cost less accumulated depreciation. Depreciation and amortization expense is recognized using the straight-line method over the following estimated useful lives:


Asset Category	Estimated Useful Life
Leasehold improvements	Shorter of estimated useful life or remaining lease term
Computer equipment	3 years
Office furniture	5 years